Details for Patent: 9,283,233

Which drugs does patent 9,283,233 protect, and when does it expire?

Patent 9,283,233 protects ELLA and is included in one NDA.

This patent has twenty-eight patent family members in twenty-three countries.

Summary for Patent: 9,283,233

Title:	Method for on-demand contraception
Abstract:	The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-(4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-- dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
Inventor(s):	Ulmann; Andre (Paris, FR), Gainer; Erin (Chardonne, CH), Mathe; Henri Camille (Paris, FR), Blithe; Diana (Silver Spring, MD), Nieman; Lynnette (Bethesda, MD)
Assignee:	LABORATOIRE HRA-PHARMA (Paris, FR) The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC)
Application Number:	14/635,107
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,283,233
Patent Claim Types: see list of patent claims	Use; Dosage form; Formulation;

Drugs Protected by US Patent 9,283,233

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Lab Hra Pharma	ELLA	ulipristal acetate	TABLET;ORAL	022474-001	Aug 13, 2010	AB	RX	Yes	Yes						METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE

International Family Members for US Patent 9,283,233

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010237120
Brazil	PI1014035
Canada	2757496
China	102395373
Cyprus	1118236